Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 PR Newswire - Tue Jan 13, 7:00AM CST

- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 PR Newswire - Tue Jan 6, 7:00AM CST

BOULDER, Colo. , Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire - Mon Jan 5, 7:00AM CST

BOULDER, Colo. , Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy PR Newswire - Wed Dec 24, 2025

–  In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; n o clinically meaningful reductions in LVEF or LVEF

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire - Tue Dec 2, 2025

BOULDER, Colo. , Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors PR Newswire - Thu Nov 20, 2025

BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire - Wed Nov 12, 2025

BOULDER, Colo. , Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers PR Newswire - Mon Nov 10, 2025

BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics to Participate in Upcoming Investor Conferences PR Newswire - Fri Nov 7, 2025

BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in...

EWTX : 27.39 (+2.97%)
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights PR Newswire - Thu Nov 6, 2025

–  Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch –

EWTX : 27.39 (+2.97%)

Barchart Exclusives

As Apple Teams Up with Google on Siri AI Upgrades, Should You Buy AAPL Stock? Barchart - 3 minutes ago
Apple’s decision to tap Google’s Gemini AI to supercharge Siri is redefining its AI strategy. Is AAPL a buy now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot